



Prevalence of multidrug resistant altered *Vibrio cholerae* O1 isolates among Diarrhoeal patients in Delhi during 2008-2012.

KEYWORDS

V. cholerae O1, VP test, D-MAMA PCR, Antibiotic susceptibility test, Phage type.

Puneeta Singh

Department of Aquatic Biotechnology, & Fisheries, MJP Rohilkhand University, Bareilly

Dhirendra Kumar

Laboratory Department, Maharishi Valmiki Infectious, Diseases Hospital, Delhi, India

Yogendra Prasad

Department of Aquatic Biotechnology, & Fisheries, MJP Rohilkhand University, Bareilly

Thandavarayan Ramamurthy

National Institute of cholera & Enteric Diseases, Kolkata

Banwari Lal Sarkar

National Institute Of Cholera & Enteric Diseases, Kolkata

Naresh Chand Sharma

Maharishi Valmiki Infectious Diseases Hospital, Delhi

ABSTRACT Altered *Vibrio cholerae* O1 has been reported from some areas in the country as well as from the other countries. Delhi is an endemic area for toxigenic *V. cholerae* O1. Therefore, we were interested to evaluate the presence of altered *Vibrios*, their drug resistance status and phage types among the strains isolated from suspected cholera/acute gastroenteritis patients admitted in this hospital. A total of 59 isolates representing different years were used for D -MAMA PCR to detect the Haitian genotype (ctxB7) strains and classical genotype (ctxB1). A subset of 49 isolates was tested to determine the phage types. All selected strains were serologically positive for *V. cholerae* O1, serotype Ogawa and biochemically biotype El Tor. The antibiotic susceptibility test explicated that 100% strains were resistant to cotrimoxazole and nalidixic acid. Phage typing revealed that 79.6% of isolates were phage type T-27. D-MAMA PCR, has shown 52.5% strains were carrying ctxB7 gene since 2008.

Introduction

Vibrio cholerae O1 biotype El Tor is an enteric bacterial pathogen causing cholera disease in many parts of Asia and Africa (WHO, 2011). It is an immense public health concern owing to its potential to produce pandemics of cholera disease in human population (Emch *et al.*, 2008). The cholera disease, caused by O1 or O139 serogroups of *V. cholerae* is generally marked with rapid loss of body fluids leading to dehydration, electrolyte disturbances and hypovolemic shock. In the absence of treatment death may occur within hours (Sack *et al.*, 2004). Recent data have shown an expansion of *V. cholerae* in different parts of India, as its various strains poses great threat being endemic (Samal *et al.*, 2008, Das *et al.*, 2008, Ramamurthy & Sharma, 2014). Developing countries like India still endure frequent outbreaks of cholera through water or food which are the main source of this pathogen in the absence of basic sanitation services and clean water (Nair *et al.*, 2007). Since the first occurrence of *V. cholerae* O1 biotype El Tor during 1964 in India and Delhi in June 1965, the constant endemicity of cholera has been noted throughout the year in Delhi (Sharma *et al.*, 2007) indicating the transformation of disease from rare prevalence to seasonal to annual (Nair, 2007). *V. cholerae* O1 biotype El Tor serotype Ogawa has always been the predominant serovar causing outbreaks in different areas of Delhi and other states except during 2004 to 2006. However, prevalence of both Ogawa and Inaba serotype in Delhi and other parts of India has also been noted (Dutta *et al.*, 2006; Das *et al.*, 2008 and Rajeshwari *et al.*, 2008).

The emergence of multiple drugs resistant isolates of *V. cholerae* (Sharma *et al.*, 2007; Kitaoka *et al.*, 2011; Kuma *et al.*, 2014) and changing pattern of antibiogram has increased interest among the scientists to reconsider the role of antibiotics in cholera epidemics. Moreover, resistance to commonly used antibiotics viz. ampicillin, tetracycline, ciprofloxacin, chloramphenicol, ceftriaxone has been found in

V. cholerae. The El Tor biotype is known to be more infective but less virulent than the classical biotype, therefore the El Tor strains that produce the classical cholera toxin is a new emerging form that appears to be causal of a more severe disease (Ghosh- Banerjee *et al.*, 2010).

In Delhi, our study showed strains of *V. cholerae* O1 belong to the altered El Tor, indicating that a cryptic change has occurred in the seventh pandemic El Tor biotype strains of *V. cholerae* O1. Therefore, this study was planned to evaluate antibiotic sensitivity of these strains and to develop a PCR based diagnostic test that could distinguish between two kinds of ctxB genes to provide a means of monitoring the presence and dissemination of the new emerging variants of *V. cholerae* O1 of the El Tor biotype in Delhi.

2. Materials and Methods:**2.1 Bacterial Strains and biochemical & Serological Characterization:**

Fresh stool specimens were obtained from patients admitted in the Maharishi Valmiki Infectious Diseases Hospital, Kingsway Camp, Delhi in 2008-2012. None had received antibiotic treatment prior to collection of the stool specimens. *V. cholerae* O1 positive 150 representative samples from the outbreaks were collected for investigation and analysis. All samples were stored in Cary Blair's transport medium, transported at ambient temperature to the laboratory within 1 hour and then plated directly on thiosulfate citrate bile salt sucrose (TCBS) agar and alkaline bile salt (BSA) agar (Himedia Mumbai, India). All strains with sucrose fermenting yellow colonies on TCBS agar and oxidase positive were further subjected to conventional biochemical tests for confirmation of *V. cholerae* as per standard protocol (CDC/WHO/USAID, 2003). All strains were biotyped by using standard procedures including susceptibility test to 50 units of polymixin B, chicken cell erythrocytes and VP test, using strains 569B & NI6961 as

the classical & El Tor reference strains respectively (Kaper et al., 1995). All strains were subjected to serogrouping and serotyping by serogroup specific O1 polyvalent anti-serum and serotype specific antiserum for Ogawa & Inaba strains, respectively (Denka Seiken, Tokyo, Japan).

2.2 Antimicrobial Susceptibility Testing:

All isolates of *V. cholerae* O1 El Tor Ogawa were tested for antimicrobial susceptibility using the disk diffusion method according to Clinical & Laboratory Standard Institute (CLSI) guidelines with commercial antibiotic discs (Hi-Media-Mumbai, India) containing ampicillin (10µg), chloramphenicol (30 µg), ciprofloxacin (5µg) gentamicin (10µg), levofloxacin (5µg), nalidixic acid(30µg), norfloxacin (10µg), streptomycin (10µg), tetracycline (30µg), trimethoprim (5µg), ceftriaxone (30µg), azithromycin (15µg), sparfloxacin (5µg), ofloxacin (5µg), furazolidone (100µg), doxycycline (30µg), cotrimoxazole (25µg). Susceptibility tests for polymixin B 50 Units in nutrient agar (Hi-media, Mumbai, India) were carried out separately by standard methods (CDC/WHO/USAID, Manual, 2003). *Escherichia coli* ATCC 25922 and *Staphylococcus aureus* ATCC 25923 were used as control strains for disc diffusion.

Isolation of genomic DNA

Overnight cultures of *V. cholerae* O1 isolates grown on Luria Agar (LA) were used for genomic DNA extraction. One loopful growth harvested from LA plate was suspended into TE buffer. After vortexing the suspension was boiled in a water bath at 100°C for 10 min and chilled in ice for 5 min followed by centrifugation at 10,000 rpm for 5 min. Supernatants were used as the genomic DNA templates (Borkakoty et al., 2012).

Determination of *ctxB1* and Haitian *ctxB7* genes of *V. cholerae* O1 strains by double mismatch amplification mutation assay (D-MAMA) PCR.

The strains were examined by double mismatch amplification mutation assay (D-MAMA) PCR for detecting the *ctxB* allele using a common reverse primer for two alleles Re-Cla(5'CCTGGTACTTCTACTTGAAACG 3') and two allele specific primers *ctxB-F3*(5'GTTTTACTATCTTCAGCATATGC GA3'), and *ctxB-F4*(5'GTTTTACTATCTTCAGCATATGCGC 3') for Haitian and classical, respectively (Naha et al., 2012).

Phage Typing

A subset of 49 strains of *Vibrio cholerae* O1 was sent to the National Institute of Cholera and Enteric Diseases (NICED), Kolkata for the phage typing. Phage typing was done as per procedures published earlier (Basu and Mukerjee., 1968; Chattopdhyay DJ et al., 1993)

3. Results:

All 150 isolates confirmed biochemical features and serologically *V. cholerae* serogroup O1 biotype El Tor serotype Ogawa. Result of AST revealed that 100% strains were sensitive to azithromycin, gentamicin, levofloxacin, ofloxacin and norfloxacin while 99.04%, 96%, 92% & 88% strains were susceptible to ceftriaxone, chloramphenicol, doxycycline and tetracycline, respectively. Conversely, all 150 strains (100%) were resistant to co-trimoxazole and nalidixic acid while 97%, 93%, 90%, 32.2% and 17.3% strains were resistant to trimethoprim, streptomycin, furazolidone, ampicillin and ciprofloxacin respectively (Table 1). The result of phage typing revealed that 79.6% of isolates were T 27 while 4% each were of T 19 and T 23 only 2 % were of T 5 types rest were untypable (Table -2). Interestingly, the D-MAMA PCR performed for 59 strains showed the pres-

ence of Haitian (*ctxB7*) (52.5%) (Fig 1a), as well as classical (*ctxB1*) (11.86%) (Fig 1b) variants.

Discussion :

All pandemics were caused by classical biotype till sixth pandemic but seventh pandemic (1961-till date) was caused by El Tor biotype and continuously caused epidemics in many countries (Ramamurthy & Sharma, 2014). In recent years, the emergence of many pathogenic variants of *V. cholerae* O1 in many Asian and African countries was recorded (Alam et al., 2010, Chin et al., 2011, Tran et al., 2012, Kumar et al., 2013, Kuma et al., 2014) indicated an epidemiology of cholera being changed. Multiple antibiotic resistant *V. cholerae* O1 has been detected from patients in MVID Hospital, Delhi from different areas during 2008-2012. Tetracycline is first line of effective drug for treatment of cholera (WHO, 2005). Previously many investigators had reported tetracycline resistance among multidrug resistant *V. cholerae* O1 (Samal et al, 2008, Sharma et al., 2007, Das et al., 2008, Sharma et al., 2015). An earlier study from this hospital recorded the circulating *V. cholerae* O1 El Tor Ogawa and Inaba strains resistant to multiple drugs viz. tetracycline, nalidixic acid, furazolidone, chloramphenicol (Dutta et al., 2006, Sharma et al., 2007, Taneja et al., 2005). Ciprofloxacin resistant strains have been circulating and this was reported by many workers and our findings are in agreement with other reports (Pal et al., 2010, Borkakoty et al., 2012, Bhattacharya et al., 2011, Kumar et al., 2013). All Haitian variants are resistant to ampicillin, nalidixic acid, cotrimoxazole, streptomycin, trimethoprim, furazolidone and some strains are ciprofloxacin resistant in present study. Many challenges are arising due to increased resistance of these drugs since many cost effective drugs are out of reach for poor people and in developing countries this has complicated the control strategies of cholera disease and moreover, result in longer hospital stay for patients. Trimethoprim, furazolidone, streptomycin, nalidixic acid and cotrimoxazole are 85-100% resistant during these years. In our study only one strain was found resistant to ceftriaxone and six strains to chloramphenicol. In this study azithromycin and levofloxacin were found sensitive hence proposed for the treatment of pregnant women and pediatric age group suffering from *V. cholerae* O1 infection. Phage typing results of 49 *V. cholerae* O1 strains on the basis of new phage typing scheme (Chattopdhyay et al., 1993) showed phage type T27 (79.6%) to be the most common type in Delhi in the present study and similar results were reported by other workers in Delhi (Das et al., 2005, Sharma et al., 2007).

Phylogenies for whole genome sequences showed that the Haiti outbreak strain is genetically related to strains originating in Nepal, India and Cameroon (Reimer et al., 2011, Son et al., 2011). Haiti isolate harbours variant of the classical *ctxB* gene (*ctxB7*). The *ctxB* gene variant *ctxB7* was first observed from Orissa, India, in 2007 (Goel et al., 2008). The strains which are carrying *ctxB7* outbreak are already present in Delhi, India since 2008, and this genotype was already reported from other parts of the country (Goel et al., 2008, Naha et al., 2012, Kutar et al., 2013, Kumar et al., 2014). Previous investigation showed that Haitian variant with higher fitness virulence and antimicrobial drug resistant phenotypes, the Haitian variants harbours infectivity and ecologic persistence advantage over the other seventh pandemic strains (Riemer et al., 2011). It appears that the Haitian variant has replaced the altered El Tor *Vibrio cholerae* O1 strains circulating in Delhi. Such direct prediction enhanced epidemiologic surveillance and will help in deciding priorities aimed at cholera prevention. In present

set of 59 strains 31 (52.5%) were found carrying *ctxB7*. In another report from Kolkata, India 93% isolates were reported to had *ctxB7* gene in 2011 (Naha *et al.*, 2012) whereas Kutar *et al.*, (2013) found only 46.2% strains having *ctxB7* gene. However in a recent report from Yavatamal and Kalamb, Maharashtra 100% strains were found to contain *ctxB7* gene (Kumar *et al.*, 2014). These reports clearly indicate that *V. cholerae* O1 strains carry *ctxB7* are replacing *V. cholerae* O1 carrying El Tor or altered *ctxB* gene.

Conclusion: The results obtained in the present study have demonstrated the emergence of multidrug resistant strains, emergence of newly encountered. Phage types and changes in the *ctxB* gene, there is urgent need to monitor the said characteristics and adopt revised strategies to control cholera disease in Delhi.

Acknowledgement: I am thankful to Medical Superintendent and all Laboratory staff of MVID Hospital, Delhi for their support.

Table1. Antibiotic resistance pattern of *Vibrio cholerae* isolates (n = 150)

Antibiotics	Serotypes Ogawa (n-150)	Resistance Overall (n-150)	Antibiotics	Serotypes Ogawa (n-150)	Resistance Overall (n-150)
Ampicilin	49/150	32.2%	Nalidixic acid	150/150	100%
Azithromycin	0/150	0%	Streptomycin	140/150	93%
Chloramphenicol	6/150	4%	Tetracycline	18/150	12%
Co-triamoxazole	150/150	100%	Trimethoprim	146/150	97%
Ceftriazone	1/150	0.06%	Levofloxacin	0/150	0%
Ciprofloxacin	26/150	17.3%	Ofloxacin	0/150	0%
Doxycycline	12/150	8%	Norfloxacin	0/150	0%
Gentamicin	0/150	0%			
Furazolidone	136/150	90%			

Table -2: Phenotypic characteristics of *V. cholerae* O1 strains (n=49) isolated from Clinical samples collected in Delhi (2008-2011)

Sl no	Place	Year	VC O1 Strain no	SEROLOGY	VP Test	Poly B (50U)	Chick cell aglu	Phage type Basu & Mukherje	Phage type new scheme
1	Delhi	2008	8169	Ogawa	+	R	+	T-2	T-27
2	Delhi	2008	8227	Ogawa	+	R	+	T-2	T-27
3	Delhi	2008	8369	Ogawa	+	R	+	T-2	T-27
4	Delhi	2008	8443	Ogawa	+	R	+	T-2	T-27
5	Delhi	2008	8930	Ogawa	+	R	+	T-2	T-27
6	Delhi	2008	9582	Ogawa	+	R	+	T-2	T-27
7	Delhi	2008	9995	Ogawa	+	R	+	UT	UT
8	Delhi	2008	10285	Ogawa	+	R	+	T-2	T-27
9	Delhi	2008	10328	Ogawa	+	R	+	T-2	T-27
10	Delhi	2008	10345	Ogawa	+	R	+	T-2	T-27
11	Delhi	2009	12535	Ogawa	+	R	+	T-2	T-27
12	Delhi	2009	13359	Ogawa	+	R	+	T-2	T-5
13	Delhi	2009	13596	Ogawa	+	R	+	T-2	T-27
14	Delhi	2009	13856	Ogawa	+	R	+	T-2	T-27
15	Delhi	2009	13799	Ogawa	+	R	+	T-2	T-27
16	Delhi	2009	14010	Ogawa	+	R	+	T-2	T-27
17	Delhi	2009	14463	Ogawa	+	R	+	T-2	T-27
18	Delhi	2009	14464	Ogawa	+	R	+	T-2	T-27
19	Delhi	2009	14581	Ogawa	+	R	+	UT	UT
20	Delhi	2009	15468	Ogawa	+	R	+	T-2	T-27
21	Delhi	2009	16368	Ogawa	+	R	+	T-2	T-27
22	Delhi	2010	20370	Ogawa	+	R	+	T-2	T-27
23	Delhi	2010	20371	Ogawa	+	R	+	T-2	T-23

24	Delhi	2010	20956	Ogawa	+	R	+	T-2	T-27
25	Delhi	2010	23979	Ogawa	+	R	+	T-2	T-27
26	Delhi	2010	23485	Ogawa	+	R	+	T-2	T-27
27	Delhi	2010	23678	Ogawa	+	R	+	UT	UT
28	Delhi	2010	23855	Ogawa	+	R	+	T-2	T-27
29	Delhi	2010	23731	Ogawa	+	R	+	T-2	T-27
30	Delhi	2010	23835	Ogawa	+	R	+	T-2	T-27
31	Delhi	2010	23902	Ogawa	+	R	+	T-2	T-27
32	Delhi	2010	20893	Ogawa	+	R	+	T-2	T-27
33	Delhi	2010	20045	Ogawa	+	R	+	T-2	T-23
34	Delhi	2011	26891	Ogawa	+	R	+	T-2	T-27
35	Delhi	2011	27071	Ogawa	+	R	+	T-2	T-19
36	Delhi	2011	27121	Ogawa	+	R	+	T-2	T-26
37	Delhi	2011	27122	Ogawa	+	R	+	T-2	T-27
38	Delhi	2011	27161	Ogawa	+	R	+	T-2	T-27
39	Delhi	2011	26973	Ogawa	+	R	+	T-2	T-27
40	Delhi	2011	26874	Ogawa	+	R	+	T-2	T-27
41	Delhi	2011	26871	Ogawa	+	R	+	T-2	T-27
42	Delhi	2011	26975	Ogawa	+	R	+	T-2	T-27
43	Delhi	2011	26976	Ogawa	+	R	+	T-2	T-27
44	Delhi	2011	26866	Ogawa	+	R	+	T-2	T-27
45	Delhi	2011	27174	Ogawa	+	R	+	T-2	T-27
46	Delhi	2011	26903	Ogawa	+	R	+	UT	UT
47	Delhi	2011	26904	Ogawa	+	R	+	T-2	T-27
48	Delhi	2011	26907	Ogawa	+	R	+	T-2	T-19
49	Delhi	2011	27169	Ogawa	+	R	+	Do	T-27

The result of phage typing (Table -3) revealed that 79.6% of isolates were T-27 while 4% were of T19 and T 23 only 2 % were of T 5 and rest were UT 8% types as diagnosed in phage typing new scheme. VP test-Voges Pauskauer test, Chick cell aggl- Chicken cell agglutinate, poly B- Polymixin B



Figure 1a; PCR with F3-ctxBCla (Rev)

Agarose gel (1.5%), Lane M 100bp Molecular weight marker, Lane no 1,(IDH00745)Haitian control strain, 2(0395)classical control, 3(N16961) El-Tor control, 4 (Negative control),5,6,7,8,9,10,11,12,13,14 (test strains).




Figure 1b; PCR with F4-ctxBCla (Rev)

Agarose gel (1.5%), Lane M 100bp Molecular weight marker, Lane no 1,(IDH00745)Haitian control strain, 2(0395)classical control, 3(N16961) El-Tor control, 4 (Negative control),5,6,7,8,9,10,11,12,13,14 (test strains).

REFERENCE

- 1 Alam M, Nusrin S, Islam A, Bhuiyan N A, Rahim N, Delgado G, Morales R, Mendez JL, Navarro A et al., (2010). Cholera between 1991 and 1997 in Mexico was associated with infection by classical, El Tor and El Tor variants of *Vibrio cholerae*. *J Clin Microbiol* 48, 3666–3674. | 2 Basu S, Mukerjee S. (1968). Bacteriophage typing of *Vibrio* El Tor. *Experientia* 24: 99-300. | 3 Bhattacharya K, Kanungo S, Sur D et al., (2011). Tetracycline resistant *Vibrio cholerae* O1 Kolkata, India. *Emerg Infect Dis* 17: 568-9. | 4 Borkakoty B, Biswas D, Devi U et al., (2012). Emergence of classical ctxB genotype 1 and tetracycline resistant strains of *Vibrio Cholerae* O1 El Tor in Assam, India. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 106: 382-386. | 5 Chin CS, Sorenson J, Harris JB, Robins WP, Charles RP, Jean-Charles RR et al. (2011). The origin of the Haitian cholera outbreak strain. *N Engl J Med* 364:33–42. | 6 Chattopdhyay DJ, Sarkar BL, Ansari MQ, Chakrabarti BK, Roy MK, Ghosh AN et al., (1993). New phage typing scheme for *Vibrio cholerae* O1 biotype El Tor strains. *J Clin Microbiol* 31:1579-85. | 7 Das S, Gupta S. (2005). Diversity of *Vibrio cholerae* strain isolated in Delhi, India during 1992-2002. *J Health Popul Nutr* 23: 44-51. | 8 Das D, Saha R, Kaur IR. (2008). Trend of antibiotic resistance of *Vibrio cholerae* strains from east Delhi. *Indian J Med Res* 127:478-82. | 9 Dutta B, Ghosh R, Sharma NC, Pazhani GP, Taneja N, Raychowdhuri A et al., (2006) Spread of cholera with newer clones of *V. cholerae* O1 El Tor serotype Inaba, in India. *J clin Microbiol* 44:3391-3. | 10 Emch M, Feldacker C, Islam MS, Ali M (2008). A seasonality of cholera from 1974 to 2005: A review of global patterns. *International Journal of Health Geographics* 7:31 doi:10.1186/1476-072X-7-31. | 11 Ghosh-Banerjee J, Senoh M, Takahashi T, Hamabata T, Barman S, Koley H et al., (2010). Cholera toxin production by the El Tor variant of *Vibrio cholerae* O1 compared to prototype El Tor and classical biotypes. *J Clin Microbiol* 48:4283–4286. | 12 Goel AK, Jain M, Kumar P, Bhadauria S, DV, Singh. (2008). A new variant of *Vibrio cholerae* O1 El Tor causing cholera in India. *J Infect* 57:280–281. | 13 Kutar BMRNS, Rajpara N, Upadhyay H, Ramamurthy T, Bhardwaj A K (2013). Clinical isolates of *V. cholerae* O1 El Tor Ogawa of 2009 from Kolkata, India: Preponderance of SXT Element and presence of Haitian ctxB variant. *PLoS ONE* 8(2):e56477 | 14 Kitaoka M, Miyata T S, Untenweger D, Pukatzki S (2011). Antibiotic resistant mechanisms of *V.cholerae*. *J Clin Microbiol* 49: 2325-2327. | 15 Kuma GK, Opintan JA, Sackey S, Nyorko K M et al., (2014). Antibiotic resistance patterns amongst clinical *Vibrio cholerae* O1 isolates from Accra, Ghana. *Int J Infect Control* v10:i3 doi: 10.3396/IJIC.v10i3.023.14. | 16 Kumar P, Mishra DK, Deshmukh DG, Jain M, Zade AM, Ingole KV, Yadava PK (2013). Haitian variant ctxB producing *Vibrio cholerae* O1 with reduced susceptibility to ciprofloxacin is persistent in Yavatmal, Maharashtra India causing cholera outbreak. *Clin Microbiol Infect* 20: 292-293. | 17 Kumar P, Mishra DK, Deshmukh DG, Jain M, Zade AM, Ingole KV et al.,(2014). *Vibrio cholerae* O1 Ogawa El Tor strains with the ctxB7 allele driving cholera outbreaks in south- western India in 2012. *Infection, Genetics and Evolution* 25:93-96. | 18 Naha A, Pazhani GP, Ganguly M, Ghosh S, Ramamurthy T, Nandy RK et al., (2012). Development and evaluation of a PCR assay for tracking the emergence and dissemination of Haitian variant ctxB in *Vibrio cholerae* O1 strains isolated from Kolkata, India. *J Clin Microbiol* 50:1733–1736. | 19 Nair GB (2007). How much more research is required to prevent cholera. *Indian J Med Res* 125: 612-14. | 20 Manual for the laboratory detection of antimicrobial susceptibility testing of bacteria pathogens of public health concern in the developing world. (2003). CDC/WHO/USAID, USA:141-159 | 21 Pal BB, Khutia HK, Samal SK, Kar SK, Patnaik B (2010). Epidemic of severe cholera caused by El Tor *Vibrio Cholerae* O1 Ogawa possessing the ctxB gene of the classical biotype in Orissa, India. *International. J Infect Dis* 14: 384-389 | 22 Rajeshwari K, Gupta A, Dubey AP, Uppal B, Singh MM (2008). Diarrhoeal outbreak of *Vibrio cholerae* O1 Inaba in Delhi. *Trop Doctor* 38:105-07. | 23 Riemer AR, Domselaar GV, Steven S, Walker M, Kent H, Tarr C, Talkington D, Rowe L et al., (2011). Comparative Genomics of *Vibrio cholerae* from Haiti, Asia and Africa. *Emerg Infect Dis* 17(11):2113-2121. | 24 Ramamurthy T and Sharma NC. (2014). Cholera outbreaks in India. *Current topics in microbiology and immunology* 379:49-85. | 25 Kaper JB, Morris JG, Levine MM. (1995). Cholera. *Clin Microbiol Rev* 8(1):48–86. | 26 Samal SK, Khantia HK, Nanda PK, Satapathy CS, Nayak SR, Sarangi AK et al., (2008). Incidence of Bacterial Enteropathogens among Hospitalized Diarrhoea Patients from Orissa, India. *Jpn J Infect Dis* 61: 350-355. | 27 Sharma NC, Mandal PK, Dhillon R, Jain M (2007). Changing profile of *Vibrio cholerae* O1, O139 in Delhi and its periphery (2003-2005). *Indian J Med Res* 125:633-40. | 28 Sharma NC, Kumar D, Sinha P, Seth DK, Gupta SK (2015). Tetracycline resistant *Vibrio cholerae* O1 Ogawa with ctxB7 allele (Haitian) is prevalent in Haryana, India. *Indian J App Res* 5(3): 376-379. | 29 Son M, Megli SCJ, Kovacicova G, Qadri F, Taylor RK (2011). Characterization of *Vibrio cholerae* O1 El Tor biotype variant clinical isolates from Bangladesh and Haiti, including a molecular genetic analysis of virulence genes. *J Clin Microbiol* 49:3739–3749. | 30 Sack DA, Sack RB, Nair GB, Siddique AK (2004). Cholera. *Lancet* 363:223-33. | 31 Taneja N, Biswal M, Tarai B, Sharma M (2005). Emergence of *Vibrio cholerae* O1 biotype El Tor serotype Inaba in North India. *Jpn J Infect Dis* 58:238-40. | 32 Tran HD, Alam M, Trung NV et al., (2012). Multidrug resistant *V. cholerae* O1 variants El Tor isolated Northern Vietnam between 2007 and 2010. *J Med Microbiol* 61:431-437. | 33 World Health Organization (2011). Cholera 2010. *Wkly Epidemiol Rec* 86:325-340. | 34 World Health Organisation (2005). The treatment of diarrhoea: a manual for physicians and other senior health workers, 4th revision. WHO/CDD/SER/80.2. Geneva: The Organization. |